{"title":"IV期乳腺癌患者肝转移性疾病的发生率在脂肪肝和非脂肪肝中相似","authors":"Adeel Haq, Tyler J Fraum, Yu Tao, Farrokh Dehdashti, Maverick LeBlanc, Mark J Hoegger, Jingqin Luo, Katherine Weilbaecher, Lindsay L Peterson","doi":"10.1177/11782234231166476","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common non-cutaneous malignancy and the second leading cause of cancer mortality in the United States. Breast cancer is a heterogeneous disease; diagnosis at an early stage renders it potentially curable, whereas advanced metastatic disease carries a worse prognosis.</p><p><strong>Objectives: </strong>To investigate whether hepatic steatosis (HS) is associated with liver metastases in patients with newly diagnosed stage IV female breast cancer patients (either de novo metastatic breast cancer or recurrent metastatic breast cancer) using non-contrast computed tomography (CT) as a marker of HS.</p><p><strong>Design: </strong>Retrospective analysis.</p><p><strong>Methods: </strong>We retrospectively identified 168 patients with stage IV breast cancer with suitable imaging from a prospectively maintained oncologic database. Three radiologists manually defined hepatic regions of interest on non-contrast CT images, and attenuation data were extracted. HS was defined as a mean attenuation <48 Hounsfield units. The frequency of hepatic metastatic disease was calculated for patient with and without HS. Relationships between HS and various patient (age, body mass index, race) and tumor (hormone receptor status, HER2 status, tumor grade) characteristics were also analyzed.</p><p><strong>Results: </strong>There were 4 patients with liver metastasis in the HS group (41 patients) versus 20 patients with liver metastases in the non-HS group (127 patients). The difference in frequencies of liver metastases among patients with (9.8%) versus without (15.7%) hepatic steatosis (odds ratio = 1.72 [0.53-7.39]) was not statistically significant (<i>P</i> = .45). Body mass index was significantly higher (<i>P</i> = .01) among patients with hepatic steatosis (32.2 ± 7.3 vs 28.8 ± 7.1 kg/m<sup>2</sup>). Otherwise, there were no significant differences between patients with versus without HS with respect to regarding age, race, hormone receptor status, HER2 status, or tumor grade.</p><p><strong>Conclusion: </strong>The frequency of hepatic metastatic disease in patients with stage IV breast cancer is similar for steatotic and non-steatotic livers.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231166476"},"PeriodicalIF":1.8000,"publicationDate":"2023-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/e2/10.1177_11782234231166476.PMC10170590.pdf","citationCount":"0","resultStr":"{\"title\":\"Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers.\",\"authors\":\"Adeel Haq, Tyler J Fraum, Yu Tao, Farrokh Dehdashti, Maverick LeBlanc, Mark J Hoegger, Jingqin Luo, Katherine Weilbaecher, Lindsay L Peterson\",\"doi\":\"10.1177/11782234231166476\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Breast cancer is the most common non-cutaneous malignancy and the second leading cause of cancer mortality in the United States. Breast cancer is a heterogeneous disease; diagnosis at an early stage renders it potentially curable, whereas advanced metastatic disease carries a worse prognosis.</p><p><strong>Objectives: </strong>To investigate whether hepatic steatosis (HS) is associated with liver metastases in patients with newly diagnosed stage IV female breast cancer patients (either de novo metastatic breast cancer or recurrent metastatic breast cancer) using non-contrast computed tomography (CT) as a marker of HS.</p><p><strong>Design: </strong>Retrospective analysis.</p><p><strong>Methods: </strong>We retrospectively identified 168 patients with stage IV breast cancer with suitable imaging from a prospectively maintained oncologic database. Three radiologists manually defined hepatic regions of interest on non-contrast CT images, and attenuation data were extracted. HS was defined as a mean attenuation <48 Hounsfield units. The frequency of hepatic metastatic disease was calculated for patient with and without HS. Relationships between HS and various patient (age, body mass index, race) and tumor (hormone receptor status, HER2 status, tumor grade) characteristics were also analyzed.</p><p><strong>Results: </strong>There were 4 patients with liver metastasis in the HS group (41 patients) versus 20 patients with liver metastases in the non-HS group (127 patients). The difference in frequencies of liver metastases among patients with (9.8%) versus without (15.7%) hepatic steatosis (odds ratio = 1.72 [0.53-7.39]) was not statistically significant (<i>P</i> = .45). Body mass index was significantly higher (<i>P</i> = .01) among patients with hepatic steatosis (32.2 ± 7.3 vs 28.8 ± 7.1 kg/m<sup>2</sup>). Otherwise, there were no significant differences between patients with versus without HS with respect to regarding age, race, hormone receptor status, HER2 status, or tumor grade.</p><p><strong>Conclusion: </strong>The frequency of hepatic metastatic disease in patients with stage IV breast cancer is similar for steatotic and non-steatotic livers.</p>\",\"PeriodicalId\":9163,\"journal\":{\"name\":\"Breast Cancer : Basic and Clinical Research\",\"volume\":\"17 \",\"pages\":\"11782234231166476\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2023-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/e2/10.1177_11782234231166476.PMC10170590.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer : Basic and Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11782234231166476\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Basic and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11782234231166476","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：在美国，乳腺癌是最常见的非皮肤恶性肿瘤，也是导致癌症死亡的第二大原因。乳腺癌是一种异质性疾病，早期诊断可能治愈，而晚期转移性疾病预后较差：使用非对比计算机断层扫描（CT）作为HS的标志物，研究肝脂肪变性（HS）是否与新诊断的IV期女性乳腺癌患者（新发转移性乳腺癌或复发性转移性乳腺癌）的肝转移有关：方法：回顾性分析：我们从前瞻性维护的肿瘤数据库中回顾性地确定了 168 名具有合适成像的 IV 期乳腺癌患者。三位放射科医生在非对比 CT 图像上手动定义肝脏感兴趣区，并提取衰减数据。HS定义为平均衰减结果：HS组（41例）有4例肝脏转移患者，而非HS组（127例）有20例肝脏转移患者。肝脏脂肪变性患者（9.8%）与非肝脏脂肪变性患者（15.7%）的肝转移频率差异（几率比=1.72 [0.53-7.39]）无统计学意义（P=0.45）。肝脂肪变性患者的体重指数明显更高（P = .01）（32.2 ± 7.3 vs 28.8 ± 7.1 kg/m2）。除此之外，有HS和无HS的患者在年龄、种族、激素受体状态、HER2状态或肿瘤分级方面没有明显差异：结论：在 IV 期乳腺癌患者中，脂肪肝和非脂肪肝患者发生肝转移性疾病的频率相似。
Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers.
Background: Breast cancer is the most common non-cutaneous malignancy and the second leading cause of cancer mortality in the United States. Breast cancer is a heterogeneous disease; diagnosis at an early stage renders it potentially curable, whereas advanced metastatic disease carries a worse prognosis.
Objectives: To investigate whether hepatic steatosis (HS) is associated with liver metastases in patients with newly diagnosed stage IV female breast cancer patients (either de novo metastatic breast cancer or recurrent metastatic breast cancer) using non-contrast computed tomography (CT) as a marker of HS.
Design: Retrospective analysis.
Methods: We retrospectively identified 168 patients with stage IV breast cancer with suitable imaging from a prospectively maintained oncologic database. Three radiologists manually defined hepatic regions of interest on non-contrast CT images, and attenuation data were extracted. HS was defined as a mean attenuation <48 Hounsfield units. The frequency of hepatic metastatic disease was calculated for patient with and without HS. Relationships between HS and various patient (age, body mass index, race) and tumor (hormone receptor status, HER2 status, tumor grade) characteristics were also analyzed.
Results: There were 4 patients with liver metastasis in the HS group (41 patients) versus 20 patients with liver metastases in the non-HS group (127 patients). The difference in frequencies of liver metastases among patients with (9.8%) versus without (15.7%) hepatic steatosis (odds ratio = 1.72 [0.53-7.39]) was not statistically significant (P = .45). Body mass index was significantly higher (P = .01) among patients with hepatic steatosis (32.2 ± 7.3 vs 28.8 ± 7.1 kg/m2). Otherwise, there were no significant differences between patients with versus without HS with respect to regarding age, race, hormone receptor status, HER2 status, or tumor grade.
Conclusion: The frequency of hepatic metastatic disease in patients with stage IV breast cancer is similar for steatotic and non-steatotic livers.
期刊介绍：
Breast Cancer: Basic and Clinical Research is an international, open access, peer-reviewed, journal which considers manuscripts on all areas of breast cancer research and treatment. We welcome original research, short notes, case studies and review articles related to breast cancer-related research. Specific areas of interest include, but are not limited to, breast cancer sub types, pathobiology, metastasis, genetics and epigenetics, mammary gland biology, breast cancer models, prevention, detection, therapy and clinical interventions, and epidemiology and population genetics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
